Publikationen, an denen er mitarbeitet Miguel González Barcia (35)

2024

  1. Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

  2. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

2023

  1. Antifungal Combination Eye Drops for Fungal Keratitis Treatment

    Pharmaceutics, Vol. 15, Núm. 1

  2. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  3. Design and biopharmaceutical preclinical characterisation of a new thermosensitive hydrogel for the removal of gastric polyps

    International Journal of Pharmaceutics, Vol. 635, pp. 122706

  4. Estudio farmacocinético de adalimumab intravítreo en un modelo de rata con uveítis mediante PET

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. A Review of Population Pharmacokinetic Analyses of Linezolid

    Clinical Pharmacokinetics, Vol. 61, Núm. 6, pp. 789-817

  2. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

  3. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 172, pp. 144-156

  4. Mucoadhesive PLGA Nanospheres and Nanocapsules for Lactoferrin Controlled Ocular Delivery

    Pharmaceutics, Vol. 14, Núm. 4

  5. PET study of intravitreal adalimumab pharmacokinetics in a uveitis rat model

    International Journal of Pharmaceutics, Vol. 627

2021

  1. Anti-inflammatory effect of tacrolimus/hydroxypropyl-β-cyclodextrin eye drops in an endotoxin-induced uveitis model

    Pharmaceutics, Vol. 13, Núm. 10

  2. Base preclínica de sistemas lipídicos nanoestructurados (NLC) cargados con bevacizumab: diseño, desarrollo y caracterización fisicoquímica

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 87-89

  3. Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment

    ACS Applied Materials and Interfaces, Vol. 13, Núm. 3, pp. 3559-3575

  4. Development and characterization of a tacrolimus/ hydroxypropyl-β-cyclodextrin eye drop

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-27

  5. Development and characterization of inhaled ethanol as a novel pharmacological strategy currently evaluated in a phase ii clinical trial for early-stage sars-cov-2 infection

    Pharmaceutics, Vol. 13, Núm. 3

  6. Diseño, desarrollo y caracterización de nanopartículas de PLGA cargadas con adalimumab

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 63-65

  7. Evaluación preclínica empleando imagen PET/CT de formulaciones impresas en 3D para el tratamiento de la Enfermedad Inflamatoria Intestinal

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 275-276

  8. In situ forming and mucoadhesive ophthalmic voriconazole/HPβCD hydrogels for the treatment of fungal keratitis

    International Journal of Pharmaceutics, Vol. 597

  9. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7